Welcome
Support Centre
06 September 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Medical Research Council/ European Blood and Marrow Transplant Prospective Randomised Trial of Autograft in Chronic Myeloid Leukaemia (CML)
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN53369512
Date ISRCTN assigned19/08/2002
Local reference number(s)MRC CML 2000 (IVa)
Public titleMedical Research Council/ European Blood and Marrow Transplant Prospective Randomised Trial of Autograft in Chronic Myeloid Leukaemia (CML)
Scientific title
AcronymN/A
Disease/condition/study domainLeukaemia (chronic)
Study hypothesisNot provided at time of registration.
Design/methodologyRandomised controlled trial.
Research ethics reviewNot provided at time of registration.
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Newly diagnosed Ph-positive and/or breakpoint cluster region (BCR)-abelson (ABL) positive CML
2. Aged 15-65
3 .Chronic phase disease
4. No contraindication to the collection of peripheral blood progenitor cells before commencing treatment
5. No major organ impairment
6. No pregnancy
Participants - exclusion criteriaNot provided at time of registration.
Patient information material
Anticipated start date01/10/1996
Anticipated end date30/10/2001
Status of trialCompleted
Target number of participantsNot provided at time of registration.
InterventionsTwo Arms:

1. Control: Interferon (IFN) Starting dose 3 x 10(6) units x 3/week escalating to 5 x 10(6) units/m(2) daily. Adjusted to maintain leukocyte count 2-4 x 10(9)/l. Use of hydroxyurea and/or ara-c optional.

2. Investigational: Mobilised or straight autograft, followed by IFN (+/- Ara-c).
Primary outcome measure(s)Not provided at time of registration.
Secondary outcome measure(s)Not provided at time of registration.
Sources of funding1. European Bone Marrow Transplantation Group
2. Medical Research Council (UK)
Sponsor nameMedical Research Council (UK)
Sponsor details20 Park Crescent
London
United Kingdom
W1B 1AL
Sponsor telephone+44 (0)20 7636 5422
Sponsor fax+44 (0)20 7436 6179
Sponsor emailclinical.trial@headoffice.mrc.ac.uk
Sponsor websitehttp://www.mrc.ac.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN53369512
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central